Establishing a mass spectrometry-based system for rapid detection of SARS-CoV-2 in large clinical sample cohorts

Karina Helena Morais Cardozo, Adriana Lebkuchen, Guilherme Gonçalves Okai, Rodrigo Andrade Schuch, Luciana Godoy Viana, Aline Nogueira Olive, Carolina dos Santos Lazari, Ana Maria Fraga, Celso Francisco Hernandes Granato, Maria Carolina Tostes Pintão and Valdemir Melechco Carvalho ()
Additional contact information
Karina Helena Morais Cardozo: Division of Research and Development, Fleury Group
Adriana Lebkuchen: Division of Research and Development, Fleury Group
Guilherme Gonçalves Okai: Division of Research and Development, Fleury Group
Rodrigo Andrade Schuch: Division of Research and Development, Fleury Group
Luciana Godoy Viana: Division of Research and Development, Fleury Group
Aline Nogueira Olive: Division of Research and Development, Fleury Group
Carolina dos Santos Lazari: Division of Infectious Diseases, Fleury Group
Ana Maria Fraga: Division of Research and Development, Fleury Group
Celso Francisco Hernandes Granato: Division of Infectious Diseases, Fleury Group
Maria Carolina Tostes Pintão: Division of Research and Development, Fleury Group
Valdemir Melechco Carvalho: Division of Research and Development, Fleury Group

Nature Communications, 2020, vol. 11, issue 1, 1-13

Abstract: Abstract The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is pressing public health systems around the world, and large population testing is a key step to control this pandemic disease. Here, we develop a high-throughput targeted proteomics assay to detect SARS-CoV-2 nucleoprotein peptides directly from nasopharyngeal and oropharyngeal swabs. A modified magnetic particle-based proteomics approach implemented on a robotic liquid handler enables fully automated preparation of 96 samples within 4 hours. A TFC-MS system allows multiplexed analysis of 4 samples within 10 min, enabling the processing of more than 500 samples per day. We validate this method qualitatively (Tier 3) and quantitatively (Tier 1) using 985 specimens previously analyzed by real-time RT-PCR, and detect up to 84% of the positive cases with up to 97% specificity. The presented strategy has high sample stability and should be considered as an option for SARS-CoV-2 testing in large populations.

Date: 2020
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-020-19925-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-19925-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-020-19925-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().